Patent · US Active

Crystalline form of N-[1-(5-cyano-pyridin-2- ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide

US11059803B2 · kind B2 · utility

1Cited by

3References

12Claims

0Family size

Assignee

IDORSIA PHARMACEUTICALS LTD · CH

Inventors

Bibia Heidmann · Allschwil, CH
Markus Von Raumer · Allschwil, CH

Key dates

Filing date	Jul 4, 2018
Grant date	Jul 13, 2021
Priority date	—
Expiry date	Jul 13, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to crystalline forms of N-[1-(5-cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide, pharmaceutical compositions comprising said crystalline forms and their use as T-type calcium channel blockers in the treatment or prevention of diseases or disorders where T-type calcium channels are involved.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.